Abstract: A process for the preparation of an extract of Ginkgo biloba leaves, comprising i. extraction of the dried fragments of Ginkgo biloba leaves in ethanol containing a maximum of 20% by weight of water; ii. concentration of the extract under reduced pressure in the presence of an aqueous solution of sodium chloride and elimination of the dark oil from the remainder of the clear solution; iii. washing of the residual aqueous solution by liquid-liquid extraction with n-hexane, n-heptane or cyclohexane, iv. liquid-liquid extraction of the aqueous phase washed with ethyl acetate; and v. washing of the ethyl acetate phase obtained in stage iv with a sodium chloride solution followed by evaporation to dryness of the washed ethyl acetate phase and use of the resulting extract to treat cerebral and peripheral vascular disorders and neurodegenerative diseases.
Type:
Grant
Filed:
April 9, 2002
Date of Patent:
May 23, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Abstract: The invention concerns a product inhibiting transduction of G heterotrimeric protein signals combined with another anti-cancer agent, in particular farnesyltransferase inhibitors, taxol or gemcitabin, for simultaneous, separate or prolonged therapeutic use in cancer treatment.
Type:
Grant
Filed:
November 8, 2000
Date of Patent:
April 25, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Grégoire Prevost, Marie-Odile Lonchampt, Thomas Gordon, Barry Morgan
Abstract: A method of treating cholera or travel diarrhea in a patient in need thereof by an effective amount of a compound of the formula wherein the substrates are defined in the specification or its non-toxic, pharmaceutically acceptable salts.
Type:
Grant
Filed:
February 3, 2003
Date of Patent:
April 25, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Grégoire Prevost, Marie-Odile Lonchampt, Thomas Gordon
Abstract: A family of tetrahydroimidazo[1,2a]pyrazine based compounds capable of inhibiting the activity of farnesyl transferase and treating tumors and restenosis having the following structure: or a pharmaceutically acceptable salt thereof, wherein the variables are as defined in the specification.
Type:
Grant
Filed:
October 18, 2002
Date of Patent:
April 4, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
Abstract: Compounds of the formula wherein R1 is alkyl and R2 is alkenyl, alkynyl, allenyl or cyanoalkyl, n is 0 or 1, k is an integer from 1 to 3, X is —(CH2)m— and m is 0 or 1; and pharmaceutical salts thereof useful for inhibiting NO synthases and/or monoamine oxydases.
Type:
Grant
Filed:
April 29, 2004
Date of Patent:
March 28, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Pierre-Etienne Chabrier De Lassauniere, Jeremiah Harnett
Abstract: The invention concerns the use of pyrido-thieno-triazolo-diazepins for preparing a medicine for treating pathological conditions or diseases involving one of the growth hormone release inhibiting factor receptors. The invention also concerns novel pyrido-thieno-triazolo-diazepins and therapeutic compositions containing them.
Type:
Grant
Filed:
June 15, 1999
Date of Patent:
March 21, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Dennis Bigg, Anne-Marie Liberatore, Jacques Pommier, John Taylor
Abstract: The invention relates to cross-linked copolymers based on non cross-linked polycarboxylic copolymers, said non cross-linked copolymers containing at least one polysaccharide. The invention also relates to a process for the preparation of these copolymers and their use in particular as a support in pharmaceutical compositions.
Type:
Grant
Filed:
October 3, 2000
Date of Patent:
March 21, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S)
Abstract: The invention relates in particular to the compounds of general formula in which R1, R2, R3, R4, R5, R6 represent various radicals; their use as medicaments and pharmaceutical compositions containing them. These compounds are particularly useful for the treatment of cancer.
Type:
Grant
Filed:
February 24, 2000
Date of Patent:
March 14, 2006
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Olivier Lavergne, Dennis Bigg, Christophe Lanco, Alain Rolland
Abstract: The invention relates to a pre-filled injection device for injecting a liquid or semisolid composition into a subject, said injection device comprising: a housing (1) containing at its distal end the liquid or semisolid composition (2), a plunger (3) arranged to slide within the housing (1) to which is affixed a plunger stick (7) extending longitudinally from the plunger to the outside of the housing (1), a hollow needle (4) affixed to the distal end of the housing (1), said needle (4) connecting the interior part of the housing (1) with the outside where it extends longitudinally, and an airtight needle shield (5) which protects said needle (4), characterized in that said device further comprises a cap (6) designed to fit around the housing's proximal end and to fully cover said plunger stick (7), said cap (6) both preventing its accidental pushing or breakage before use and being adapted to receive the injection device once the injection into the subject has been carried out.
Type:
Grant
Filed:
October 22, 2002
Date of Patent:
October 11, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S)
Inventors:
Christophe Aubert, Roland Cherif-Cheikh
Abstract: The present invention is directed to peptide analogues of fragment of parathyroid hormone (PTH) or parathyroid hormone-related protein (PTHrP), a method of using said analogues alone or in combination with a bisphosphonate or calcitonin to treat osteoporosis and pharmaceutical compositions comprising said analogues alone or in combination with a bisphosphonate or calcitonin.
Type:
Grant
Filed:
November 6, 2002
Date of Patent:
July 26, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
Abstract: A novel class of analogs which exhibit both high affinity and selectivity for Neuromedin B and Somatostann receptors are claimed. One example is Nal-Tyr-cyclo(D-Cys-D-Trp-Lys-D-Cys)-Abu-Nal-NH2.
Type:
Grant
Filed:
June 5, 2000
Date of Patent:
June 7, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
Abstract: The present invention is directed to peptide analogues of glucagon-like peptide-1, the pharmaceutically-acceptable salts thereof, to methods of using such analogues to treat mammals and to pharmaceutical compositions useful therefor comprising said analogues.
Type:
Grant
Filed:
December 7, 1999
Date of Patent:
June 7, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S
Abstract: An injection device for intramuscular or subcutaneous injection of solid or semi-solid medicaments is disclosed. The device includes main body member having a needle attached thereto. A protective sleeve covers the needle and retracts into the main body member when the device is pressed against the skin of a patient. A plunger with an attached rod maintains the medicament in the patient as the needle is withdrawn.
Type:
Grant
Filed:
September 26, 2002
Date of Patent:
May 24, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
Abstract: Compounds of formula wherein the substituents are as defined in the specification which compounds are useful for inhibiting the activity of NO-synthase enzymes.
Type:
Grant
Filed:
April 21, 2003
Date of Patent:
May 3, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Jeremiah Harnett, Michel Auguet, Pierre-Etienne Chabrier de Lassauhyere
Abstract: The invention concerns novel mikanolide derivatives, their preparation method and their therapeutic uses, in particular as anti-cancer and anti-viral agents.
Type:
Grant
Filed:
January 11, 2002
Date of Patent:
May 3, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Olivier Lavergne, Christophe Lanco, Grégoire Prevost, Beng Poon Teng
Abstract: The invention concerns a product comprising at least a NO synthase inhibiting substance associated with at least a phospholipase A2 inhibiting substance, separately or combined, for simultaneous therapeutic use, separately or spread over time for treating pathologies in which nitrogen monoxide and/or phospholipases A2 are involved. The invention also concerns a pharmaceutical composition comprising, an active principle, at least a NO synthase inhibiting substance and at least a phospholipase A2 inhibiting substance, and optionally a pharmaceutically acceptable.
Type:
Grant
Filed:
November 3, 2000
Date of Patent:
March 29, 2005
Assignee:
Societe de Conseils de Recherches et D'Applications Scientifiques (S.C.R.A.S.)
Inventors:
Michel Auguet, Pierre-Etienne Chabrier de Lassauniere
Abstract: A method of spherifying a sustained release ionic conjugate which contains a free carboxyl group-containing polymer and a free amino group-containing drug which are ionically bonded to each other.
Type:
Grant
Filed:
January 26, 2000
Date of Patent:
March 15, 2005
Assignees:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S., Poly-Med, Incorporated
Inventors:
Shalaby Wahba Shalaby, Steven A. Jackson, Jacques-Pierre Moreau
Abstract: The present invention is directed to cyclic peptides of formula (I): X-A1-cyclo(D-Cys-A3-A4-Lys-A6-A7)-A8-Y, or a pharmaceutically acceptable salt thereof. The peptides bind selectively to the somatostatin subtype receptor type-5 and elicit an agonist effect from the somatostatin subtype receptors.
Type:
Grant
Filed:
June 23, 2000
Date of Patent:
March 8, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S.A.S.
Abstract: The present invention is directed to imidazolyl derivatives of the formula: where the substituents are defined in the specification, or a pharmaceutically acceptable salt thereof. The derivatives bind selectively to the somatostatin subtype receptors and elicit either an agonist or antagonist effect from the somatostatin subtype receptors.
Type:
Grant
Filed:
June 8, 1999
Date of Patent:
February 8, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques, S. A. S.
Inventors:
Christophe Alain Thurieau, Lydie Francine Poitout, Marie-Odile Galcera, Christophe Philippe Moinet, Thomas D. Gordon, Barry A. Morgan
Abstract: The invention concerns a product comprising at least an inhibitor of heterotrimeric G protein signal transduction, associated with at least another anti-hypertensive agent, in particular calcium channel blockers and conversion enzyme inhibitors, for simultaneous, separate or prolonged therapeutic use, in the treatment of hypertension.
Type:
Grant
Filed:
January 5, 2001
Date of Patent:
January 25, 2005
Assignee:
Societe de Conseils de Recherches et d'Applications Scientifiques (S.C.R.A.S.)